Abstract
Introduction. Adverse events of anticancer therapy in gastric cancer remain a major clinical challenge, often limiting the completion of the full treatment course. Disruption of trace element homeostasis may contribute to the development of toxic complications and could be considered a potential basis for therapy personalization.
Aim. To assess the association between plasma concentrations of copper, zinc, selenium, and manganese and the incidence, nature, and severity of toxic complications from anticancer drug therapy in patients with locally advanced and metastatic gastric cancer.
Materials and Methods. The study included 100 patients with newly diagnosed gastric cancer who underwent four courses of chemotherapy. Trace element concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS, Varian 810-MS) immediately before the first and fifth courses of anticancer drug therapy. Adverse event severity was graded according to CTCAE v5.0. Statistical analysis employed Spearman's correlation.
Results. The absolute plasma concentrations of trace elements (copper, zinc, selenium, and manganese) in gastric cancer patients before the first and fifth courses of chemotherapy remained within established reference ranges and showed weak correlation with the incidence, nature, and severity of adverse events (p > 0.05). However, plasma trace element ratios demonstrated significant correlations. The pre-treatment copper/zinc ratio correlated with reduced severity of leukopenia (r = –0.331; p = 0.046) and diarrhea (r = –0.331; p = 0.001). The pre-treatment selenium/manganese ratio was associated with decreased severity of anemia (r = –0.211; p = 0.036). Furthermore, the pre-treatment copper/manganese ratio (r = –0.206), pre-treatment zinc/selenium ratio (r = –0.199), and the copper/zinc ratio measured after the fourth chemotherapy course (r = –0.241) all demonstrated statistically significant inverse correlations with diarrhea severity (p < 0.05 for all).
Conclusion. Predictive significance lies not in the absolute plasma concentrations of the studied trace elements before and during treatment, but in their ratios. These findings indicate the potential of incorporating trace element ratios into multivariate predictive models of toxicity, where they could serve as additional significant markers alongside genetic, clinical, laboratory, and instrumental predictors.
References
Al-Batran S.E., Homann N., Pauligk C., et al. FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro–oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393(10184): 1948–1957.-DOI: https://doi.org/10.1016/S0140-6736(18)32557-1.-URL: https://pubmed.ncbi.nlm.nih.gov/30982686.
Bang Y.J., Kim Y.W., Yang H.K., et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315–21.-DOI: https://doi.org/10.1016/S0140-6736(11)61873-4.-URL: https://pubmed.ncbi.nlm.nih.gov/22226517.
Andre T., Boni C., Mounedji-Boudiaf L., et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23): 2343–51.-DOI: https://doi.org/10.1056/NEJMoa032709.-URL: https://pubmed.ncbi.nlm.nih.gov/15175436.
Федоринов Д.С., Лядова М.А., Лядов В.К. Переносимость периоперационной химиотерапии при раке желудка в реальной клинической практике: проспективное исследование. Современная онкология. 2024; 26(3): 291–295.-DOI: https://doi.org/10.26442/18151434.2024.3.202954.-URL: https://modernonco.orscience.ru/18151434/article/download/635383/pdf. [Fedorinov D.S., Lyadova M.A., Lyadov V.K. Tolerability of perioperative chemotherapy for gastric cancer in real clinical practice. Journal of Modern Oncology. 2024; 26(3): 291–295.-DOI: https://doi.org/10.26442/18151434.2024.3.202954.-URL: https://modernonco.orscience.ru/18151434/article/download/635383/pdf (In Rus)].
Chen P., Bornhorst J., Aschner M. Manganese metabolism in humans. Front Biosci (Landmark Ed). 2018; 23(9): 1655–1679.-DOI: https://doi.org/10.2741/4665.-URL: https://pubmed.ncbi.nlm.nih.gov/29293455.
Aschner M., Erikson K. Manganese. Adv Nutr. 2017; 8(3): 520–521.-DOI: https://doi.org/10.3945/an.117.015305.
Jiang S., Li X., Zhang F., et al. Manganese dioxide-based nanocarrier delivers paclitaxel to enhance chemotherapy against orthotopic glioma through hypoxia relief. Small Methods. 2022; 6(7): e2101531.-DOI: https://doi.org/10.1002/smtd.202101531.-URL: https://pubmed.ncbi.nlm.nih.gov/35587180.
Holm I., Hernroth B., Rosander A., et al. Manganese as a possible anticancer enhancer in docetaxel treatment of prostate cancer cells. Anticancer Res. 2024; 44(3): 953–962.-DOI: https://doi.org/10.21873/anticanres.16890.-URL: https://pubmed.ncbi.nlm.nih.gov/38423638.
Janowska M., Potocka N., Paszek S., et al. An assessment of serum selenium concentration in women with endometrial cancer. Nutrients. 2022; 14(5): 958.-DOI: https://doi.org/10.3390/nu14050958.-URL: https://pubmed.ncbi.nlm.nih.gov/35267933.
Tanini D., Carradori S., Capperucci A., et al. Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action. Eur J Med Chem. 2021; 225: 113793.-DOI: https://doi.org/10.1016/j.ejmech.2021.113793.-URL: https://pubmed.ncbi.nlm.nih.gov/34507012.
Lin S., Yang H. Ovarian cancer risk according to circulating zinc and copper concentrations: A meta-analysis and Mendelian randomization study. Clin Nutr. 2021; 40(4): 2464–2468.-DOI: https://doi.org/10.1016/j.clnu.2020.10.011.-URL: https://pubmed.ncbi.nlm.nih.gov/33129595.
Prasad A.S. Zinc in human health: effect of zinc on immune cells. Mol Med. 2008; 14(5–6): 353–7.-DOI: https://doi.org/10.2119/2008-00033.Prasad.-URL: https://pubmed.ncbi.nlm.nih.gov/18385818.
Avery J.C., Hoffmann P.R. Selenium, Selenoproteins, and immunity. Nutrients. 2018; 10(9): 1203.-DOI: https://doi.org/10.3390/nu10091203.-URL: https://pubmed.ncbi.nlm.nih.gov/30200430.
Mocchegiani E., Malavolta M., Lattanzio F., et al. Cu to Zn ratio, physical function, disability, and mortality risk in older elderly (ilSIRENTE study). Age (Dordr). 2012; 34(3): 539–52.-DOI: https://doi.org/10.1007/s11357-011-9252-2.-URL: https://pubmed.ncbi.nlm.nih.gov/21544579.
Mocchegiani E., Romeo J., Malavolta M., et al. Zinc: dietary intake and impact of supplementation on immune function in elderly. Age (Dordr). 2013; 35(3): 839–60.-DOI: https://doi.org/10.1007/s11357-011-9377-3.-URL: https://pubmed.ncbi.nlm.nih.gov/22222917.
Lubos E., Loscalzo J., Handy D.E. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2011 Oct 1; 15(7): 1957–97.-DOI: https://doi.org/10.1089/ars.2010.3586.-URL: https://pubmed.ncbi.nlm.nih.gov/21087145.
Министерство здравоохранения Российской Федерации. Клинические рекомендации по лечению рака желудка, редакция от 2020 года.-URL: https://cr.minzdrav.gov.ru/recomend/574_1. [Ministry of Health of the Russian Federation. Clinical guidelines: gastric cancer. 2020.-URL: https://cr.minzdrav.gov.ru/recomend/574_1 (In Rus)].
Malavolta M., Giacconi R., Piacenza F., et al. Plasma copper/zinc ratio: an inflammatory/nutritional biomarker as predictor of all-cause mortality in elderly population. Biogerontology. 2010; 11(3): 309–19.-DOI: https://doi.org/10.1007/s10522-009-9251-1.-URL: https://pubmed.ncbi.nlm.nih.gov/19821050.
Torii Y., Naito K., Takagi J., et al. Examination of the relationship between serum zinc levels and peripheral neuropathy induced by paclitaxel/carboplatin combination therapy in gynecological cancer patients. Fujita Med J. 2025; 11(1): 11–19.-DOI: https://doi.org/10.20407/fmj.2024–013.-URL: https://pubmed.ncbi.nlm.nih.gov/39896227.
Скальная М.Г. Клиническая микроэлементология. Москва: Практическая медицина. 2024; 280.-ISBN: 978-5-98811-773-5. [Skalnaya M.G. Clinical Micronutrientology. Moscow: Practical Medicine. 2024; 280.-ISBN: 978-5-98811-773-5 (In Rus)].
Tefas C., Ciobanu L., Berce C., et al. Beneficial effect of oral administration of zinc sulfate on 5-fluorouracil-induced gastrointestinal mucositis in rats. Eur Rev Med Pharmacol Sci. 2020; 24(21): 11365–11373.-DOI: https://doi.org/10.26355/eurrev_202011_23628.-URL: https://pubmed.ncbi.nlm.nih.gov/33215457.
Prasad A.S. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009; 12(6): 646–52.-DOI: https://doi.org/10.1097/MCO.0b013e3283312956.-URL: https://pubmed.ncbi.nlm.nih.gov/19710611.
Chung J.H., Phalke N., Hastings C., et al. Zinc deficiency and its association with treatment-related toxicity in children with cancer. Pediatr Blood Cancer. 2021; 68(9): e29104.-DOI: https://doi.org/10.1002/pbc.29104.-URL: https://pubmed.ncbi.nlm.nih.gov/34061438.
Станоевич И.В., Хвостовой В.В., Петроченко Д.В., et al. Фундаментальные аспекты биохимии селена и селенопротеинов: прикладное значение в онкологии. Сибирский онкологический журнал. 2024; 23(5): 157–169.-DOI: https://doi.org/10.21294/1814-4861-2024-23-5-157-169.-URL: https://elibrary.ru/download/elibrary_75144793_34681832.pdf. [Fundamental aspects of selenium and selenoprotein biochemistry: applied significance in oncology. Stanoyevich I.V., Khvostovoy V.V., Petrochenko D.V., et al. Siberian Journal of Oncology. 2024; 23(5): 157–169.-DOI: https://doi.org/10.21294/1814-4861-2024-23-5-157-169.-URL: https://elibrary.ru/download/elibrary_75144793_34681832.pdf (In Rus)].
Gaetke L.M., Chow-Johnson H.S., Chow C.K. Copper: toxicological relevance and mechanisms. Arch Toxicol. 2014; 88(11): 1929–38.-DOI: https://doi.org/10.1007/s00204-014-1355-y.-URL: https://pubmed.ncbi.nlm.nih.gov/25199685.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2026
